FDA Drug Watch: Cancer Breakthrough, Herpes Treatment & Recalls

The latest FDA watch delivers a powerful mix of hope and caution across cancer breakthroughs, herpes treatment advances, and urgent recalls.

Patients and providers now track fresh approvals that reshape care for tough cancers and stubborn viral infections while companies pull certain products from the market to protect public safety.

These developments highlight how the FDA balances innovation with vigilance.

This also offers new options for stage III colon cancer and resistant herpes sores, even as quality concerns trigger widespread recalls of everyday pain relievers and anesthetic injectables.

Stay alert to these shifts because they directly affect treatment choices and product safety in clinics and homes nationwide.

Companies Under Recent FDA Scrutiny Include:

• Roche for a major cancer therapy expansion
• Asahi Kasei for a novel herpes treatment approval
• Aurobindo Pharma for a large-scale paracetamol recall
• Par Health for an anesthetic injection recall

Also Read: How Can Indian Pharma Strengthen Quality Amid Rising FDA Scrutiny

Cancer Breakthrough: Roche Secures New Adjuvant Option for Stage III Colon Cancer

Roche advances cancer care with FDA approval of Tecentriq (atezolizumab) and Tecentriq Hybreza in combination with a fluoropyrimidine and oxaliplatin. This regimen targets the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer after surgery.

Study Reveals:

• The landmark phase III ATOMIC study showed that adding Tecentriq to modified FOLFOX6 chemotherapy cuts the risk of disease recurrence or death by 50 percent compared with chemotherapy alone.
• At 36 months, disease-free survival reached 86 percent in the Tecentriq group versus 76 percent with chemotherapy only.
• Nearly 25 percent of colon cancers present at stage III, and almost one in three of those patients face recurrence within five years. About 15 percent of colon cancers carry dMMR or MSI-H features that make them especially responsive to immunotherapy.

This approval marks the twelfth U.S. indication for Tecentriq and establishes the first approved adjuvant immunotherapy regimen for this specific population. Levi Garraway, Roche’s Chief Medical Officer, noted that the combination holds potential to become the new standard of care.

Frank A. Sinicrope of the Mayo Clinic called the results practice-changing for patients who previously lacked mismatch-repair-specific options after surgery.

Herpes Treatment Advance: Asahi Kasei Gains Approval for Resistant Infections

Asahi Kasei now offers a long-awaited option for adults with weakened immune systems. The FDA clears HOVILPRI (pritelivir) 100 mg tablets to treat stubborn herpes sores on the skin and mucous membranes when standard drugs like acyclovir, valacyclovir, or famciclovir fail to work.

How the Drug Performs:

• Pritelivir stands out as a first-of-its-kind oral drug. It targets the virus in a completely new way by blocking the proteins the herpes virus needs to copy its genetic material.
• Older treatments need a viral enzyme to activate them first, and mutations can shut that process down. Pritelivir skips that step entirely, so it keeps working against many resistant infections.

A Trial Outcome Shows:

• A late-stage trial with 101 patients shows clear results. Nearly 63 percent of people who take pritelivir see their sores heal completely within 28 days.
• Only 34 percent heal fully with the doctor’s choice of older options such as intravenous foscarnet, cidofovir, or imiquimod.
• The most common side effects people report include headache, diarrhea, nausea, reduced appetite, vomiting, and dizziness.

Stacy Wheeler, CEO of Asahi Kasei Therapeutics in the U.S. and Europe, calls the approval the first new mechanism of action for these hard-to-treat herpes lesions in nearly 30 years.

The company plans to make the drug available in the United States before the end of 2026. This step fills a real gap for roughly 15,000 U.S. patients whose weakened immune systems leave them vulnerable to persistent, painful sores.

Key Recalls: Quality Concerns Prompt Action from Aurobindo Pharma and Par Health

Aurobindo Pharma’s U.S. arm initiated a voluntary recall of 112,932 bottles of acetaminophen (paracetamol) after consumer complaints of tablet discoloration.

The recall covers three pack sizes: 90,456 bottles of 500-count, 7,836 of 1,000-count, and 14,640 of 200-count. The company began the action on September 18.

The FDA has not yet classified the severity. Acetaminophen remains a widely used over-the-counter option for mild-to-moderate pain and fever and appears in more than 600 formulations.

Similarly, Par Health issued a voluntary nationwide recall of two lots of Brevital Sodium 500 mg/vial (methohexital sodium for injection) to the hospital level.

The company detected particulate matter identified as cellulose in lots 86930 (expiry 02/2028) and 88623 (expiry 04/2028).

Injecting product containing particulate matter carries a reasonable probability of life-threatening consequences such as pulmonary emboli, blood-vessel occlusions, tissue death, organ damage, or vein inflammation that may lead to clotting.

Par Health has received no reports of adverse events related to this recall. Healthcare providers must stop use and distribution of the affected lots and arrange returns through Inmar, Inc.

Final Takeaway

These concurrent FDA actions underscore the agency’s dual role in clearing innovative therapies while enforcing manufacturing standards. Patients with stage III dMMR colon cancer and immunocompromised individuals facing stubborn herpes sores gain meaningful new options, yet the recalls remind everyone to stay vigilant about product quality.

Healthcare professionals should review the latest prescribing information and recall notices to guide decisions and protect patients.